Surgical menopause
This is not medical advice — it is general information based on what you searched for that may help.
General information based on published sources and the symptoms you searched for. This isn't medical or legal advice, a diagnosis or a treatment plan. Please consult a doctor about your own symptoms. If your symptoms are severe or sudden, seek urgent care.
Evidence:Strong evidence
This page may not apply to you if:
- Applies when both ovaries are removed (bilateral oophorectomy); if a hysterectomy kept one or both ovaries, menopause does not happen immediately
Surgical menopause occurs when both ovaries are removed surgically (bilateral oophorectomy), with or without a hysterectomy. Unlike natural perimenopause — where hormone levels shift over several years — surgical menopause causes an immediate drop in ovarian estrogen, progesterone, and androgen production.
In a 2025 JMIR study of 627 people seeking menopause information (including 69 in surgical menopause), respondents reported that online resources rarely distinguished sudden surgical menopause from natural midlife menopause.
Key differences in symptoms and treatment planning
- Abrupt symptom onset: Hot flashes, night sweats, sleep disruption, and vaginal dryness can begin within days or weeks of surgery and are often more severe than in natural menopause.
- Bone and cardiovascular protection: When oophorectomy takes place before age 45 (and especially before age 40), systemic hormone therapy is usually recommended at least until the average age of natural menopause to prevent rapid bone loss, unless contraindicated (for example, by a hormone-sensitive cancer).
- Estrogen-alone vs combined HRT: In women who have also had a total hysterectomy (no uterus), systemic estrogen can typically be given without a progestogen (the FDA boxed warning for endometrial cancer applies to unopposed systemic estrogen in people with an intact uterus), though clinicians may still include progestogen in specific histories such as endometriosis.
- When hormones are contraindicated: If ovary removal was performed because of a hormone-sensitive cancer, Level I non-hormonal treatments and evidence-graded strategies in our Does It Work? directory can be planned with your oncology team.
Questions to ask before or after surgery
Add these to your printable sheet in the treatment conversation builder:
- Will my surgery remove one or both ovaries, and can we have a symptom and bone-protection plan ready before discharge?
- Am I a candidate for systemic estrogen therapy after surgery, and do I need a progestogen given my surgical history?
- When should we schedule a follow-up to review vasomotor symptoms, sleep, sexual function, and bone density?
Where are you right now?
Still tracking
Not sure if your symptoms fit? Start tracking your daily patterns.
Log and spot your patterns with the symptom checklist →Ready to talk to a doctor
Have an upcoming appointment? Bring structured questions and your history.
Prepare your 10-minute doctor appointment questions →Already on treatment
Evaluating your response or wondering what to adjust next?
Explore evidence-graded treatment and lifestyle options →Questions people ask
Is a hysterectomy the same as surgical menopause?
Only if both ovaries are removed (bilateral oophorectomy) at the same time. Removing the uterus alone stops menstrual periods, but if one or both ovaries remain, they continue producing hormones until menopause occurs later.
Why are hot flashes often more intense after surgical menopause?
Natural perimenopause involves a gradual transition over several years, whereas removing both ovaries causes an overnight drop in estradiol, progesterone, and ovarian testosterone.
Related pages
References
- Funnell EL, McConnell F, Martin-Key NA et al.. Understanding Experiences of and Unmet Needs in Online Searches for Menopause Information: An Exploratory Survey. JMIR Formative Research, 2025.
- The 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause (The North American Menopause Society, now The Menopause Society), 2022. Funding: Funded by donations to the NAMS Education & Research Fund; the statement reports no commercial support. Individual panel disclosures not yet reviewed..
- FDA Requests Labeling Changes Related to Safety Information to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies. U.S. Food and Drug Administration, 2025.
- Shufelt CL, Brown V, Carpenter JS et al.. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause (The North American Menopause Society, now The Menopause Society), 2023.
Change log
- : Published clinical guide on surgical menopause